clofibric acid has been researched along with Kidney Diseases in 10 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A systematic review of cohort studies, randomized trials, voluntary notifications to national regulatory authorities, and published case reports was undertaken to assess the incidence and characteristics of adverse effects in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins." | 2.43 | Statin safety: a systematic review. ( Law, M; Rudnicka, AR, 2006) |
| "Myositis was significantly associated with statin monotherapy (RR 2." | 1.34 | Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. ( Glanz, M; Hokanson, JE; McClure, DL; Murphy, JR; Valuck, RJ, 2007) |
| " It is concluded that, from a pharmacokinetic point of view, a reduction in the dosage of ciprofibrate should be considered in patients with a glomerular filtration rate below 30 ml min-1/1." | 1.28 | The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate. ( Bernard, N; Cuisinaud, G; Ferry, N; Gardes, E; Labeeuw, M; Pozet, N; Sassard, J; Zech, PY, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, X | 1 |
| Law, M | 1 |
| Rudnicka, AR | 1 |
| McClure, DL | 1 |
| Valuck, RJ | 1 |
| Glanz, M | 1 |
| Murphy, JR | 1 |
| Hokanson, JE | 1 |
| Abshagen, U | 1 |
| Kösters, W | 1 |
| Kaufmann, B | 1 |
| Lang, PD | 1 |
| Hong, SK | 1 |
| Anestis, DK | 1 |
| Brown, PI | 1 |
| Rankin, GO | 1 |
| Broeders, N | 1 |
| Knoop, C | 1 |
| Antoine, M | 1 |
| Tielemans, C | 1 |
| Abramowicz, D | 1 |
| Tsimihodimos, V | 1 |
| Kakafika, A | 1 |
| Elisaf, M | 1 |
| Lipscombe, J | 1 |
| Bargman, JM | 1 |
| Zimetbaum, P | 1 |
| Frishman, WH | 1 |
| Kahn, S | 1 |
| Ferry, N | 1 |
| Bernard, N | 1 |
| Pozet, N | 1 |
| Gardes, E | 1 |
| Cuisinaud, G | 1 |
| Labeeuw, M | 1 |
| Zech, PY | 1 |
| Sassard, J | 1 |
2 reviews available for clofibric acid and Kidney Diseases
| Article | Year |
|---|---|
Statin safety: a systematic review.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Clofibric Acid; Cre | 2006 |
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; | 1991 |
8 other studies available for clofibric acid and Kidney Diseases
| Article | Year |
|---|---|
Prevention of local lipotoxicity: a new renoprotective mechanism of peroxisome proliferator-activated receptor-alpha activation in hypertension and obesity?
Topics: Animals; Clofibric Acid; Dietary Fats; Humans; Hypertension; Hypolipidemic Agents; Kidney Diseases; | 2009 |
Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population.
Topics: Age Factors; Aged; Clofibric Acid; Cohort Studies; Confidence Intervals; Confounding Factors, Epidem | 2007 |
Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure.
Topics: Adult; Bezafibrate; Clofibrate; Clofibric Acid; Drug Administration Schedule; Female; Humans; Kidney | 1980 |
Effect of glucuronidation substrates/inhibitors on N-(3,5-dichlorophenyl)succinimide nephrotoxicity in Fischer 344 rats.
Topics: Animals; Biotransformation; Blood Urea Nitrogen; Camphanes; Clofibric Acid; Drinking; Eating; Eugeno | 1999 |
Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
Topics: Bezafibrate; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidem | 2000 |
Fibrate treatment can increase serum creatinine levels.
Topics: Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Ki | 2001 |
Fibrate-induced increase in blood urea and creatinine.
Topics: Bezafibrate; Blood Urea Nitrogen; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Humans; Hyp | 2001 |
The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.
Topics: Adult; Aged; Clofibrate; Clofibric Acid; Female; Fibric Acids; Humans; Hypolipidemic Agents; Kidney | 1989 |